ADA 2026: This Could Be E-NuSH To Get Us Excited

Research evidence excerpt

ADA 2026: This Could Be E-NuSH To Get Us Excited

dosing, as expected; however, the symptoms improved rapidly with more dosing. As a key call out, the phase 3

dose-escalation scheme is intended to reduce such events. On trial, 83% of treated participants reported none

or only mild GI AEs (i.e., nausea, vomiting, diarrhea, constipation). There were very few severe GI AEs on trial.

We'd point out, though, that per the speaker, the study was generally small and conducted in a limited number

of sites, and that tends to be the major driver of the variability in the trials we see today with regard to GI AE

discontinuations.

Summary and discussion. The things that differentiate berobenatide from its competitors are first and foremost its

HALO technology mentioned above which allows for the half life of 15-16 days. This makes titration-free dosing and

monthly dosing possible, as well as better tolerability and improved scalability. On scalability, that means a 5-10 fold

lower dose can produce the same weight and glycemic effects as semaglutide—and from a financial perspective, lower

COGS. The fully-biased profile was again highlighted to allow for zero the beta-arrestin recruitment, which is what

potentially contributes to much of the unfavorable GI side effect profile.

●What did we learn from these phase 2 trials? There is promise with berobenatide. It could provide a more tolerable

profile with good efficacy and a shorter titration schedule for weekly dosing. The trials further showed that

monthly dosing is feasible, and we were reminded that these phase 2 trials are intended to show that the drug

works and is safe once we find an optimal dose. VESPER-4 and -5 will look at weekly dosing, while VESPER-6

will take on monthly administration.